Individual detection of 14 high risk human papilloma virus genotypes by the PapType test for the prediction of high grade cervical lesions

Journal of Clinical Virology

Volumn 60, Issue 1, 2014, Pages 44-49

  Cuzick, Jack ^a   Ho, Linda ^a   Terry, George ^a   Kleeman, Michelle ^a   Giddings, Michael ^a   Austin, Janet ^a   Cadman, Louise ^a   Ashdown Barr, Lesley ^a   Costa, Maria J ^a   Szarewski, Anne ^a  

^a QUEEN MARY UNIVERSITY OF LONDON   (United Kingdom)

Author keywords

Cervix; CIN; Genotypes; High risk HPV; Positive predictive value

Indexed keywords

ADULT; ARTICLE; CANCER CYTODIAGNOSIS; CANCER GRADING; CANCER RISK; CERVICAL INTRAEPITHELIAL NEOPLASIA 2; CERVICAL INTRAEPITHELIAL NEOPLASIA 3; CLINICAL CLASSIFICATION; DIAGNOSTIC ACCURACY; DIAGNOSTIC TEST ACCURACY STUDY; DISEASE ASSOCIATION; FEMALE; GENOTYPE; HIGH RISK HUMAN PAPILLOMA GENOTYPE; HIGH RISK PATIENT; HUMAN; HUMAN PAPILLOMAVIRUS DNA TEST; HUMAN PAPILLOMAVIRUS TYPE 16; HUMAN PAPILLOMAVIRUS TYPE 18; HUMAN PAPILLOMAVIRUS TYPE 31; HUMAN PAPILLOMAVIRUS TYPE 33; HUMAN PAPILLOMAVIRUS TYPE 35; HUMAN PAPILLOMAVIRUS TYPE 39; HUMAN PAPILLOMAVIRUS TYPE 45; HUMAN PAPILLOMAVIRUS TYPE 51; HUMAN PAPILLOMAVIRUS TYPE 52; HUMAN PAPILLOMAVIRUS TYPE 56; HUMAN PAPILLOMAVIRUS TYPE 58; HUMAN PAPILLOMAVIRUS TYPE 59; HUMAN PAPILLOMAVIRUS TYPE 66; HUMAN PAPILLOMAVIRUS TYPE 68; INFECTION RISK; INTERMETHOD COMPARISON; MAJOR CLINICAL STUDY; MIXED INFECTION; PAP SCREENING SYSTEM; PAPANICOLAOU TEST; PAPTYPE TEST; PREDICTION; PREDICTIVE VALUE; PRIORITY JOURNAL; RECEIVER OPERATING CHARACTERISTIC; RISK ASSESSMENT; RISK FACTOR; SENSITIVITY AND SPECIFICITY; UTERINE CERVIX CARCINOMA IN SITU; UTERINE CERVIX CYTOLOGY; UTERINE CERVIX DISEASE; VIRUS DETECTION; WART VIRUS; CERVICAL INTRAEPITHELIAL NEOPLASIA; CLASSIFICATION; GENETICS; GENOTYPING TECHNIQUE; ISOLATION AND PURIFICATION; PAPILLOMA VIRUS; PROCEDURES; REPRODUCIBILITY; UTERINE CERVIX; VIROLOGY;

CERVICAL INTRAEPITHELIAL NEOPLASIA; CERVIX UTERI; FEMALE; GENOTYPE; GENOTYPING TECHNIQUES; HUMANS; PAPANICOLAOU TEST; PAPILLOMAVIRIDAE; PREDICTIVE VALUE OF TESTS; REPRODUCIBILITY OF RESULTS; SENSITIVITY AND SPECIFICITY;

EID: 84899049861     PISSN: 13866532     EISSN: 18735967     Source Type: Journal    
DOI: 10.1016/j.jcv.2014.02.002     Document Type: Article

References (22)

1. Bouvard V., Baan R., Straif K., Grosse Y., Secretan B., El Ghissassi F., et al. Special report, policy. A review of human carcinogens. Part B. Lancet Oncol 2009, 10:321-322.
2. IARC IARC Monographs on Evaluation of Carcinogenic Risks to Humans 2009, vol. 100B.
3. Cuschieri K.S., Cubie H.A., Whitley M.W., Seagar A.L., Arends M.J., Moore C., et al. Multiple high risk HPV infections are common in cervical neoplasia and young women in a cervical screening population. J Clin Path 2004, 57:68-72.
4. Stevens M.P., Garland S.M., Rudland E., Tan J., Quinn M.A., Tabrizi S.N. Comparison of the Digene Hybrid Capture 2 assay and Roche AMPLICOR and LINEAR ARRAY human papillomavirus (HPV) tests in detecting high-risk HPV genotypes in specimens from women with previous abnormal pap smear results. J Clin Microbiol 2007, 45:2130-2137.
5. Szarewski A., Ambroisine L., Cadman L., Austin J., Ho L., Terry G., et al. Comparison of predictors for high grade cervical intraepithelial neoplasia in women with abnormal smears. Cancer Epidemiol Biomarkers Prev 2008, 17:3033-3042.
6. Castle P.E., Stoler M.H., Wright T.C., Sharma A., Wright T.L., Behrens C.M. Performance of carcinogenic human papillomavirus (HPV) testing and HPV16 or HPV18 genotyping for cervical cancer screening of women aged 25 years and older, a subanalysis of the ATHENA study. Lancet 2011, 12:880-890.
7. Tan S.E., Garland S.M., Rumboid A.R., Tabrizi S.N. Comparison of the INNO-LiPA and PapType assays for detection of human papillomavirus in archival vulva dysplasia and/or neoplasia tissue biopsy specimens. J Clin Microbiol 2011, 49:3980-3982.
8. Tabrizi S.N., Stevens M.P., Khan Z.A., Chow C., Devitt M.A., Garland S.M. Comparison of PapType to Digene Hybrid Capture, Roche Linear Array and Amplicor for detection of high risk human papillomavirus genotypes in women with previous abnormal pap smears. J Clin Microbiol 2012, 50:2796-2798.
9. Szarewski A., Mesher D., Cadman L., Austin J., Ashdown-Barr L., Ho L., et al. A comparison of seven tests for high grade cervical intraepithelial neoplasia in women with abnormal smears, the Predictors 2 study. J Clin Microbiol 2012, 50:1867-1873.
10. Tjalma W.A., Fiander A., Reich C., Powell N., Nowakowski A.M., Kirschner B., et al. Differences in human papillomavirus type distribution in high-grade cervical intraepithelial neoplasia an invasive cancer in Europe. Int J Cancer 2013, 132:854-867.
11. Tjalma W.A.A., Depuydt C.E., Stoler M.H., Wright T.L. Don't forget HPV-45 in cervical cancer screening. Am J Clin Pathol 2012, 137:161-163.
12. Sanjose S., Quint W.G., Alemony L., Geroets D.T., Klaustemeier J.E., Lloveras B., et al. Human papillomavirus genotype attribution in invasive cervical cancer, a retrospective cross-sectional worldwide study. Lancet 2010, 11:1048-1056.
13. Wheeler C.M., Hunt W.C., Cuzick J., Langsfeld E., Pearson A., Montoya G.D., et al. A population-based study of human papillomavirus genotype prevalence in the United States: baseline measures prior to mass papillomavirus vaccination. Int J Cancer 2012, 132:198-207.
14. Bulkmans N.W.J., Bleeker M.C.G., Berkhof J., Voorhortst F.J., Snijders P.J.F., Meijer C.J.L.M. Prevalence of types 16 and 33 is increased in high-risk human papillomavirus positive women with cervical intraepithelial neoplasia grade 2 or worse. Int J Cancer 2005, 117:177-181.
15. Naucler P., Ryd W., Tornberg S., Strand A., Wadell G., Hansson B.G., et al. HPV type-specific risks of high-grade CIN during 4 years of follow-up: a population-based prospective study. BJC 2007, 97:129-132.
16. Wheeler C.M., Hunt W.C., Joste N.E., Key C.R., Quint W.G.V., Castle P.E. Human papillomavirus genotype distributions, Implications for vaccination and cancer screening in the United States. J Natl Cancer Inst 2009, 101:475-487.
17. Insinga R.P., Perez G., Wheeler C.M., Koutsky L.A., Garland S.M., Leodolter S., et al. Incident cervical HPV infections in young women: transition probabilities for CIN and infection clearance. Cancer Epidemiol Biomarkers Prev 2011, 20:287-296.
18. Chen H.C., Schiffman M., Lin C.Y., Pan M.H., You S.L., Chuang L.C. Persistence of type-specific Human Papilloma virus infection and increased long-term risk of cervical cancer. JNCI 2012, 103:1387-1396. CBCSP-HPV Study Group.
19. Schiffman M., Glass A.G., Wentzensen N., Rush B.B., Castle P.E., Scott D.R., et al. A long-term prospective study of type-specific human papillomavirus infection and risk of cervical neoplasia among 20,000 women in the Portland Kaiser cohort study. Cancer Epidemiol Biomarkers Prev 2011, 20. 1398-1391.
20. Castle P.E., Shaber R., LaMere B.J., Kinney W., Fetterma B., Poitras N., et al. Human papillomavirus (HPV) genotypes in women with cervical precancer and cancer at Kaiser Permanente Northern California. Caner Epidemiol Biomarkers Prev 2011, 20:946-953.
21. Cox J.T., Castle P.E., Behrens C.M., Sharma A., Wright T.C., Cuzick J., et al. Comparison of cervical cancer screening strategies incorporating different combinations of cytology, HPV testing, and genotyping for HPV16/18, results from the ATHENA HPV study. Am J Obstet Gynecol 2013, 208:184e1-184e11.
22. Wentzensen N., Schiffman M., Dunn S.T., Zuna R.E., Gold M.A., Allen R.A., et al. Multiple HPV genotype infections in cervical cancer progression in the study to understand cervical cancer early endpoints and determinants (SUCCEED). Int. J Cancer 2009, 125:2151-2158.